Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

In the original version of this article (1), the analysis presented in the text, figures (Figs. 1 and 2), and supplementary data (Supplementary Fig. S2; Supplementary Table S1) included data from one patient who withdrew consent after enrollment/data collection but prior to analysis. This error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.